Effects of an immersive psychosocial training program on depression and well-being: A randomized clinical trial.


Journal

Journal of psychiatric research
ISSN: 1879-1379
Titre abrégé: J Psychiatr Res
Pays: England
ID NLM: 0376331

Informations de publication

Date de publication:
06 2022
Historique:
received: 21 10 2021
revised: 08 02 2022
accepted: 28 02 2022
pubmed: 17 4 2022
medline: 18 5 2022
entrez: 16 4 2022
Statut: ppublish

Résumé

Psychiatry stands to benefit from brief non-pharmacological treatments that effectively reduce depressive symptoms. To address this need, we conducted a single-blind randomized clinical trial assessing how a 6-day immersive psychosocial training program, followed by 10-min daily psychosocial exercises for 30 days, improves depressive symptoms. Forty-five adults were block-randomized by depression score to two arms: (a) the immersive psychosocial training program and 10-min daily exercise group (36 days total; total n = 23; depressed at baseline n = 14); or (b) a gratitude journaling control group (36 days total; total n = 22; depressed at baseline n = 13). The self-report PHQ-9 was used to assess depression levels in both groups at three time points: baseline, study week one, and study week six. Depression severity improved over time, with a significantly greater reduction in the psychosocial training program group (-82.7%) vs. the control group (-23%), p = 0.02 for baseline vs. week six. The effect size for this reduction in depression symptoms was large for the intervention group (d = -1.3; 95% CI, -2.07, -0.45; p < 0.001) and small for the control group (d = -0.3; 95% CI, -0.68, 0.03; p = 0.22). Seventy-nine percent (11/14) of depressed participants in the intervention condition were in remission (PHQ-9 ≤ 4) by week one and 100% (14/14) were in remission at week six. Secondary measures of anxiety, stress, loneliness, and well-being also improved by 15-80% in the intervention group (vs. 0-34% in the control group), ps < 0.05. Overall, this brief, immersive psychosocial training program rapidly and substantially improved depression levels and several related secondary outcomes, suggesting that immersive interventions may be useful for reducing depressive symptoms and enhancing well-being.

Identifiants

pubmed: 35429739
pii: S0022-3956(22)00115-7
doi: 10.1016/j.jpsychires.2022.02.034
pmc: PMC9107501
mid: NIHMS1798916
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

292-299

Subventions

Organisme : NHGRI NIH HHS
ID : T32 HG000044
Pays : United States

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Références

Maturitas. 2017 Dec;106:48-56
pubmed: 29150166
CNS Drugs. 2014 Jul;28(7):601-9
pubmed: 24831418
PLoS One. 2012;7(7):e41778
pubmed: 22860015
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Cleve Clin J Med. 2006 Apr;73(4):351-3, 356-61
pubmed: 16610395
Mayo Clin Proc. 2007 Nov;82(11):1395-402
pubmed: 17976360
Lancet. 2018 Nov 24;392(10161):2299-2312
pubmed: 30396512
JAMA Psychiatry. 2021 May 1;78(5):481-489
pubmed: 33146667
CNS Drugs. 2009 Aug;23(8):627-47
pubmed: 19594193
J Am Assoc Nurse Pract. 2019 Sep;31(9):497-501
pubmed: 30829971
JAMA Intern Med. 2014 Mar;174(3):357-68
pubmed: 24395196
J Affect Disord. 2016 Sep 15;202:67-86
pubmed: 27253219
J Psychiatr Res. 2016 Jun;77:42-51
pubmed: 26978184
Psychol Bull. 2014 May;140(3):774-815
pubmed: 24417575
J Clin Psychol. 2012 Apr;68(4):382-9
pubmed: 24469930
Nat Med. 2019 Dec;25(12):1822-1832
pubmed: 31806905
Innov Clin Neurosci. 2019 Jul 01;16(7-08):12-17
pubmed: 31832258
Qual Life Res. 2010 Feb;19(1):111-23
pubmed: 20047086
Front Psychiatry. 2019 Feb 28;10:101
pubmed: 30890970
Soc Psychiatry Psychiatr Epidemiol. 2019 Jul;54(7):803-811
pubmed: 30627758
Am J Psychiatry. 2006 Jan;163(1):28-40
pubmed: 16390886
EMBO Rep. 2016 Sep;17(9):1245-9
pubmed: 27491723
Am Psychol. 2005 Jul-Aug;60(5):410-21
pubmed: 16045394
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Depress Anxiety. 2017 Sep;34(9):801-808
pubmed: 28419611
Psychother Psychosom. 2020;89(5):283-306
pubmed: 32259826

Auteurs

Ariel B Ganz (AB)

Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.

Benjamin Rolnik (B)

Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.

Meenakshi Chakraborty (M)

Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.

Jacob Wilson (J)

Applied Science and Performance Institute, Department of Human Performance Research, Tampa, FL, USA.

Cyrus Tau (C)

Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.

Matthew Sharp (M)

Applied Science and Performance Institute, Department of Human Performance Research, Tampa, FL, USA.

Dallen Reber (D)

Applied Science and Performance Institute, Department of Human Performance Research, Tampa, FL, USA.

George M Slavich (GM)

Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA. Electronic address: gslavich@mednet.ucla.edu.

Michael P Snyder (MP)

Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: mpsnyder@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH